|
|
|
|
||
slide 6, "Robust pipeline of genomic medicines" looks very impressive1 trial in P3 4 trials in P1/2 13 preclinical indications that's the "depth and breath" that everyone here thinks should justify a much higher valuation I hope that SM speaks to some bullish specifics of that depth and breath at next week's ER |
return to message board, top of board |